1 Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, Collet JP; 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases. The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1; 39(9):763–816.
2 Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 3/1985 1985; 71(3):510–5.
3 Criqui MH, Vargas V, Denenberg JO, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. Oct 25 2005;112(17):2703–7.
4 Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. Jama. Sep 19 2001;286(11):1317–24.
5 Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2016;62:1642–51.
6 Cambou JP, Aboyans V, Constans J, Lacroix P, Dentans C, Bura A. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery. May 2010;39(5):577–85.
7 Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. Dec 3 2005;366(9501):1925–34.
8 Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. Jama. Mar 21 2007;297(11):1197–206.
9 Hirsch AT, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006;113:463–654.
10 Xu D, Zou L, Xing Y, et al. Diagnostic value of ankle-brachial index in peripheral arterial disease: a meta-analysis. The Canadian journal of cardiology. Apr 2013;29(4):492–8.
11 Diehm C, Darius H, Pittrow D, Allenberg J. Der Knöchel-Arm-Index: ein wegweisender Risikomarker für die hausärztliche Praxis. Dt. Ärzteblatt. 2005; 102(34):A2310–3.
12 Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation: 15;104;2001.
13 Ouwendijk R, Kock MC, van Dijk LC, van Sambeek MR, Stijnen T, Hunink MG. Vessel wall calcifications at multi-detector row CT angiography in patients with peripheral arterial disease: effect on clinical utility and clinical predictors. Radiology. Nov 2006;241(2):603–8.
14 Langenberger H, Schillinger M, Plank C, et al. Agreement of duplex ultrasonography vs. computed tomography angiography for evaluation of native and in-stent SFA re-stenosis--findings from a randomized controlled trial. European journal of radiology. Sep 2012;81(9):2265–9.
15 Collins R, Burch J, Cranny G, et al. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. Bmj. Jun 16 2007; 334(7606):1257.
16 Ouriel K. Peripheral arterial disease. Lancet. 10/13/2001 2001;358(9289):1257–64.
17 Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Medical management of peripheral arterial disease. Journal of thrombosis and haemostasis: JTH. Aug 2005;3(8):1628–37.
18 European Association for Cardiovascular P, Rehabilitation, Reiner Z, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European heart journal. Jul 2011;32(14):1769–818.
19 Schulte K. Interventionelle endovaskuläre Therapie bei Patienten mit peripherer arterieller Verschlusskrankheit-Ballonangioplastie. VASA. Zeitschrift für Gefasskrankheiten. 2004;33(Suppl. 64):5–7.
20 Nordanstig J, Gelin J, Hensater M, Taft C, Osterberg K, Jivegard L. Walking performance and health-related quality of life after surgical or endovascular invasive versus non-invasive treatment for intermittent claudication--a prospective randomised trial. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery. Aug 2011; 42(2):220–7.
21 Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation. Oct 1994;90(4):1866–74.
22 Steinacker J, Liu Y, Hanke H. Körperliche Bewegung bei peripherer arterieller Verschlusskrankheit. Deutsches Ärzteblatt. 2002;45:2550–4.
23 Saxton JM, Zwierska I, Blagojevic M, Choksy SA, Nawaz S, Pockley AG. Upper- versus lower-limb aerobic exercise training on health-related quality of life in patients with symptomatic peripheral arterial disease. Journal of vascular surgery. May 2011;53(5):1265–73.
24 Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. The New England journal of medicine. 12/12/2002 2002;347(24):1941–51.
25 Beckitt TA, Day J, Morgan M, Lamont PM. Calf muscle oxygen saturation and the effects of supervised exercise training for intermittent claudication. Journal of vascular surgery. Aug 2012;56(2):470–5.
26 Amendt K. Ist der allgemein akzeptierte therapeutische Nutzen des Gehtrainings bei Patienten mit arterieller Verschlusskrankheit evidenzbasiert? Analyse des Cochrane-Reviews. Hämostaseologie 2006;26:224–8.
27 Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby GSystematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012 Dec; 99(12):1630–8.
28 Pratt CM. Analysis of the cilostazol safety database. The American journal of cardiology. Jun 28 2001; 87(12A):28D–33D.
29 Stewart M, Morling JR, Maxwell H. Padma 28 for intermittent claudication. Cochrane Database Syst Rev. 2016 Mar 29;3:CD007371
30 Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Mar 21;135 (12):e726–e779.
31 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. Nov 16 1996;348(9038):1329–39.
32 Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. Feb 2012; 141(2 Suppl):e669S–690.
33 Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. New Engl J Med. 2017;5;376(1):32–40.
34 Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 20; 354 (16):1706–17.
35 Branch KR, Probstfield JL, Eikelboom JW, et al. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation. 2019;140:529–37.
36 Anand SS, Eikelboom JW, Dyal L, et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. J Am Coll Cardiol 2019; 73:3271–80.